C-IIISchedule III Controlled Substance (USA)
References in periodicals archive ?
As of March 31, 2011, C-III was named special servicer on 13,537 loans in 115 CMBS transactions with an unpaid principal balance (UPB) of $140.
Excellent recovery results with challenging assets: During 2013, C-III resolved a high percentage of loans and real estate owned (REO) assets held in its inventory, while achieving overall successful net recoveries on loan and REO liquidations.
28, 2011, Fitch was notified of a proposal to transfer the CDO collateral asset management responsibilities for the above mentioned CDOs from C-III Asset Management LLC to C-III Investment Management LLC, both of which are subsidiaries of C-III Capital Partners LLC.
C-III is a leading commercial real estate services company engaged in a broad range of activities, including primary and special loan servicing, loan origination, fund management, CDO management, principal investment, title services and multifamily property management.
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.
Since that time, C-III has successfully launched mortgage origination, investment sales and title insurance businesses and it has expanded its principal investment, loan origination, fund management, and primary and special loan servicing businesses.
The LPL and apo C-III genes, for example, are respectively stimulated and repressed by fibrate therapy and dietary fatty acids [14-16].
Farkas is the founder, chairman, and chief executive officer of Island Capital Group LLC and C-III Capital Partners LLC.
In a Phase 1 trial, CAT-2003 demonstrated significant reductions in fasting and post-prandial triglyceride levels and had positive effects on lipid biomarkers including reductions in LDL, apolipoprotein C-III (ApoC-III), ApoB and PCSK9.
JERIT's new external manager is C-III JERIT Manager LLC (the "New Manager"), and JERIT and the New Manager entered into an amended and restated management agreement on August 30.
Rx] as a monotherapy and achieved statistically significant mean reductions of up to 80 percent in apolipoprotein C-III (apoC-III) and up to 71 percent in triglycerides.